Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against adult cat fleaCtenocephalides felisand flea egg production in cats

Abstract

Esafoxolaner, a purified enantiomer of afoxolaner with insecticidal and acaricidal properties, is combined with eprinomectin and praziquantel in NexGard® Combo, a novel topical endectoparasiticide formulation for cats. The efficacy of this novel formulation against adult and immature stages of Ctenocephalides felis fleas was tested in four experimental studies. Two studies were designed to test adulticide efficacy, one to test inhibition of immature stages, and one to test both adulticide efficacy and inhibition of immature stages. In each study, cats were randomly allocated to a placebo control group or to a novel formulation group treated once at the minimum recommended dose. Cats were experimentally infested weekly for one to two months with unfed C. felis originating from North America or Europe. For adulticide efficacy evaluations, live fleas were counted 24 h after treatment and after subsequent weekly infestations. For immature stages, flea eggs were collected and counted weekly for evaluation of egg production inhibition and incubated for larval hatching evaluation. In the three studies testing adult fleas, curative efficacies, 24 h after treatment, were 92.1%, 98.3% and 99.7%; preventive weekly efficacies, 24 h after weekly infestations, remained higher than 95.5% for at least one month. In the two studies testing immature stages, egg production and larval hatching was significantly reduced for at least one month. These studies provide robust evidence of efficacy of the novel formulation against experimental adult flea infestations and for the prevention of environmental contamination by immature flea stages, for at least one month.

Immediate and long-term efficacy of Felpreva®, a new spot-on formulation containing tigolaner, emodepside and praziquantel, applied as a single application to cats artificially infested with the cat flea Ctenocephalides felis

“…A single spot-on application of sarolaner and selamectin (Stronghold® Plus for cats, Zoetis) at minimum doses of 1 ​mg and 6 ​mg per kg BW demonstrated persistent efficacy (97.7%) over five weeks (Day 35) ( Becskei et al., 2017 ). One treatment with esafoxolaner in combination with eprinomectin and praziquantel (Nexgard® Combo spot-on for cats, Boehringer-Ingelheim Animal Health) at minimum doses of 1.44 ​mg, 0.48 ​mg and 10 ​mg per kg BW, respectively, provided efficacy rates between 95.5% and 99.8% four weeks after treatment (Day 28) and variable efficacy thereafter ( Tielemans et al., 2021 ). A single, oral treatment with lotilaner (Credelio®, Elanco Animal Health) at the minimum dose of 6 ​mg lotilaner per kg BW has demonstrated full flea efficacy for five weeks and prevented weekly flea reinfestations within eight hours for four weeks (97.8% on Day 35) ( Cavalleri et al., 2018 ).…”

Efficacy of two endectoparasiticide products combining fipronil and (S)-methoprene or esafoxolaner with eprinomectin and praziquantel against fleas and intestinal helminths in cats naturally infested in Brazil

“…Broadline Ò has been used safely for several years [8] and was demonstrated to be efficacious against a broad spectrum of feline parasites, including fleas [1] and gastro-intestinal helminths [13,24]. NexGard Ò Combo was recently developed and registered in the European Union [9] and was demonstrated to be efficacious against fleas in experimental infestation studies conducted with isolates originating from France, South Africa and the USA [25], and in field studies with naturally infested cats from Europe, the USA and Australia [27], and against gastrointestinal helminths using induced and natural models of infection with isolates originating from Europe, North America and South Africa [12]. The safety of NexGard Ò Combo was also comprehensively demonstrated, namely in specific target animal safety studies [10,26].…”